BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 20237034)

  • 21. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
    J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical significance of standardized uptake value in breast cancer measured using 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Kim YH; Lee JA; Baek JM; Sung GY; Lee DS; Won JM
    Nucl Med Commun; 2015 Aug; 36(8):790-4. PubMed ID: 25932535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.
    Avril N; Menzel M; Dose J; Schelling M; Weber W; Jänicke F; Nathrath W; Schwaiger M
    J Nucl Med; 2001 Jan; 42(1):9-16. PubMed ID: 11197987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK; Nakamoto Y; Kanao S; Tanaka S; Sugie T; Mikami Y; Toi M; Togashi K
    AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective Correlation of Prognostic Immunohistochemical Markers With SUV and ADC Derived From Dedicated Hybrid Breast 18F-FDG PET/MRI in Women With Newly Diagnosed Breast Cancer.
    Morawitz J; Kirchner J; Martin O; Bruckmann NM; Dietzel F; Li Y; Rischpler C; Herrmann K; Umutlu L; Bittner AK; Mohrmann S; Ingenwerth M; Häberle L; Esposito I; Antoch G; Buchbender C; Sawicki LM
    Clin Nucl Med; 2021 Mar; 46(3):201-205. PubMed ID: 33351505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
    Martoni AA; Zamagni C; Quercia S; Rosati M; Cacciari N; Bernardi A; Musto A; Fanti S; Santini D; Taffurelli M
    Cancer; 2010 Feb; 116(4):805-13. PubMed ID: 20052718
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
    Kurland BF; Peterson LM; Lee JH; Linden HM; Schubert EK; Dunnwald LK; Link JM; Krohn KA; Mankoff DA
    J Nucl Med; 2011 Oct; 52(10):1541-9. PubMed ID: 21903739
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strong association of epidermal growth factor receptor status with breast cancer FDG uptake.
    Lee J; Lee EJ; Moon SH; Kim S; Hyun SH; Cho YS; Choi JY; Kim BT; Lee KH
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1438-1447. PubMed ID: 28488029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Standard uptake value of 18F-fluorine-2-deoxyglucose is correlated with the expression of estrogen receptor in duct carcinoma of breast].
    Wen GH; Feng YL; Deng HF; Yu FZ; Liu DJ; Yuan JW; He XH; Huang KM; Liu SS; Yang M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 May; 39(3):448-50. PubMed ID: 18575338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic value of
    Nguyen A; Fullard K; Sheehan-Dare G; Tang R; Chan L; Ho B; Dear R; Keane J; Hickey A; Nandurkar R; Chen J; Chen A; Lim E; Emmett L
    J Med Imaging Radiat Oncol; 2022 Sep; 66(6):731-737. PubMed ID: 34676675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metabolic activity of breast cancer metastatic lesions on positron emission tomography/computed tomography: comparison with histological and biological characteristics of primary tumor.
    Sobic Saranovic D; Stojiljkovic M; Susnjar S; Odalovic S; Artiko V; Pavlovic S; Grozdic-Milojevic I; Obradovic V
    Neoplasma; 2016; 63(2):313-21. PubMed ID: 26774154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of primary tumor SUV
    Yoo J; Yoon HJ; Kim BS
    Ann Nucl Med; 2017 Jan; 31(1):19-28. PubMed ID: 27645144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with
    Lemarignier C; Martineau A; Teixeira L; Vercellino L; Espié M; Merlet P; Groheux D
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1145-1154. PubMed ID: 28188325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased FDG uptake in breast cancer is associated with prognostic factors.
    Sanli Y; Kuyumcu S; Ozkan ZG; Işik G; Karanlik H; Guzelbey B; Turkmen C; Ozel S; Yavuz E; Mudun A
    Ann Nucl Med; 2012 May; 26(4):345-50. PubMed ID: 22359222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma.
    Choi BB; Kim SH; Kang BJ; Lee JH; Song BJ; Jeong SH; Yim HW
    World J Surg Oncol; 2012 Jun; 10():126. PubMed ID: 22741544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes.
    Koo HR; Park JS; Kang KW; Cho N; Chang JM; Bae MS; Kim WH; Lee SH; Kim MY; Kim JY; Seo M; Moon WK
    Eur Radiol; 2014 Mar; 24(3):610-8. PubMed ID: 24097303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer.
    Ueda S; Kondoh N; Tsuda H; Yamamoto S; Asakawa H; Fukatsu K; Kobayashi T; Yamamoto J; Tamura K; Ishida J; Abe Y; Yamamoto M; Mochizuki H
    BMC Cancer; 2008 Dec; 8():384. PubMed ID: 19102762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.